✓. Onset of GBS symptoms within 2 weeks prior to enrollment;
✓. GBS-DS score of 3-5;
✓. Written informed consent obtained.
Exclusion criteria
✕. Patients with GBS symptoms for more than 2 weeks;
✕. Known hypersensitivity of the study subject to any component of the investigational drug or any other anti-neonatal Fc receptor (FcRn) agent;
✕. Any uncontrolled active infection or severe infection within 8 weeks prior to screening;
✕. Patients with other autoimmune diseases, such as Sjögren's syndrome, systemic lupus erythematosus, neuromyelitis optica, myasthenia gravis, multiple sclerosis, etc., requiring treatment with immunosuppressive agents;
✕. Vaccination within 4 weeks prior to screening or planned vaccination during the study period;
✕. Pregnant or breastfeeding, or planning to become pregnant during the study period, or women of childbearing potential not using effective contraception;
✕. Currently participating in another clinical trial of similar investigational agents (FcRn antagonists);